key: cord-0740117-jvyiipbb authors: Lucinde, R. K.; Mugo, D.; Bottomley, C.; Karani, A.; Gardiner, E.; Aziza, R.; Gitonga, J.; Karanja, H.; Nyagwange, J.; Tuju, J.; Wanjiku, P.; Nzomo, E.; Kamuri, E.; Thuranira, K.; Agunda, S.; Nyutu, G.; Etyang, A.; Adetifa, I. M. O.; Kagucia, E.; Uyoga, S.; Otiende, M.; Otieno, E.; Ndwiga, L.; Agoti, C. N.; Aman, R. A.; Mwangangi, M.; Amoth, P.; Kasera, K.; Nyaguara, A.; Nganga, W.; Ochola, L. B.; Namdala, E.; Gaunya, O.; Okuku, R.; Barasa, E.; Bejon, P.; Tsofa, B.; Ochola-Oyier, L. I.; Warimwe, G. M.; Agweyu, A.; Scott, J. A. G.; Gallagher, K. E. title: Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: repeated cross-sectional surveys 2020-21 date: 2022-03-06 journal: nan DOI: 10.1101/2022.03.03.22271860 sha: 05f6d693f3acd4cef44050abd8d0835d329a8453 doc_id: 740117 cord_uid: jvyiipbb Introduction The high proportion of SARS-CoV-2 infections that have remained undetected presents a challenge to tracking the progress of the pandemic and estimating the extent of population immunity. Methods We used residual blood samples from women attending antenatal care services at three hospitals in Kenya between August 2020 and October 2021and a validated IgG ELISA for SARS-Cov-2 spike protein and adjusted the results for assay sensitivity and specificity. We fitted a two-component mixture model as an alternative to the threshold analysis to estimate of the proportion of individuals with past SARS-CoV-2 infection. Results We estimated seroprevalence in 2,981 women; 706 in Nairobi, 567 in Busia and 1,708 in Kilifi. By October 2021, 13% of participants were vaccinated (at least one dose) in Nairobi, 2% in Busia. Adjusted seroprevalence rose in all sites; from 50% (95%CI 42-58) in August 2020, to 85% (95%CI 78-92) in October 2021 in Nairobi; from 31% (95%CI 25-37) in May 2021 to 71% (95%CI 64-77) in October 2021 in Busia; and from 1% (95% CI 0-3) in September 2020 to 63% (95% CI 56-69) in October 2021 in Kilifi. Mixture modelling, suggests adjusted cross-sectional prevalence estimates are underestimates; seroprevalence in October 2021 could be 74% in Busia and 72% in Kilifi. Conclusions There has been substantial, unobserved transmission of SARS-CoV-2 in Nairobi, Busia and Kilifi Counties. Due to the length of time since the beginning of the pandemic, repeated cross-sectional surveys are now difficult to interpret without the use of models to account for antibody waning. Globally, as countries are confronted with new waves of SARS-CoV-2 infections and new variants, As vaccine coverage and vaccine-induced immunity is still considered to be low in Kenya, it remains 73 important to track the potential protection conferred by natural infection. By the 31 st October 2021, 74 Kenya had experienced four waves of infections, and reported a total of 253,310 confirmed cases and 75 5281 deaths. However, with just 3.9% of the population over 65 years of age(4), the proportion of 76 infections that have been asymptomatic is likely to be very high(5). Additionally, limited access to 77 tests and low uptake of testing makes it likely that a substantial proportion of cases have remained 78 undetected. Measuring the prevalence of antibodies to SARS-CoV-2 is an alternative way to estimate 79 the cumulative incidence of infection. A number of serological assays have been developed and 80 perform well with high sensitivity and specificity(6-9). We have shown that 5.2% of blood donors in 81 Kenya had SARS-CoV-2 antibodies in June 2020 and this had risen to 9.1% in September 2020 and 82 48.5% by March 2021(10-12). However, it is unclear whether blood donors are representative of the 83 population. In the context of a pandemic, sentinel public health surveillance using residual aliquots of routinely 85 collected blood samples has the potential to overcome participation bias. For example, sero-86 surveillance for HIV among women attending antenatal care was used to track the progress of the 87 HIV pandemic and showed prevalence estimates that were similar to population samples from the . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 6, 2022. (Table 182 2). Just 6 (2%) of women were vaccinated in October 2021, and seroprevalence remained 71% among 183 the unvaccinated. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 6, 2022. Table 2 ). . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Modelling indicates the first wave could have predominantly affected communities of low-income . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 6, 2022. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. pandemic than any one estimate alone. The impact of pregnancy on susceptibility to SARS-CoV-2 infection is unclear (15) . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 6, 2022. ; https://doi.org/10.1101/2022.03.03.22271860 doi: medRxiv preprint World Health Organization. Africa faces 470 million COVID-19 vaccine shortfall in 2021 Population and Housing Census (www.knbs.or.ke) SARS-CoV-2 388 infection hospitalization, severity, criticality, and fatality rates A serological 390 assay to detect SARS-CoV-2 seroconversion in humans Evaluation of nine commercial SARS-CoV-2 immunoassays Test performance 394 evaluation of SARS-CoV-2 serological assays Meta-analysis of 396 diagnostic performance of serological tests for SARS-CoV-2 antibodies and public health 397 implications Seroprevalence of 399 anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors Temporal trends 402 of SARS-CoV-2 seroprevalence in transfusion blood donors during the first wave of the COVID-19 403 epidemic in Kenya Prevalence of 405 SARS-CoV-2 Antibodies From a National Serosurveillance of Kenyan Blood Donors Comparison of HIV prevalence estimates from antenatal care 408 surveillance and population-based surveys in sub-Saharan Africa Sentinel surveillance for HIV-1 among pregnant women in a developing country: 3 years' experience 412 and comparison with a population serosurvey Clinical manifestations, 416 risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living 417 systematic review and meta-analysis Obstetrical outcomes and 419 follow-up for patients with asymptomatic COVID-19 at delivery: a multicenter prospective cohort 420 study Ministry of HK, National ACCK, Kenya Medical Research I, 422 National Council for P, Development/Kenya. Kenya Demographic and Health Survey RStan: the R interface to Stan Quantifying 427 previous SARS-CoV-2 infection through mixture modelling of antibody levels Stringent 430 thresholds for SARS-CoV-2 IgG assays result in under-detection of cases reporting loss of taste/smell Rapid 433 Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19 Persistence 436 of IgG response to SARS-CoV-2. The Lancet Infectious Diseases Revealing the extent of the 441 COVID-19 pandemic in Kenya based on serological and PCR-test data The immunology of asymptomatic SARS-CoV-2 infection: what are 444 the key questions? Expert Committee on Biological Standardisation: Establishment of the 447 WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody Seroprevalence and 450 clinical spectrum of SARS-CoV-2 infection in the first versus third trimester of pregnancy Post 453 lockdown COVID-19 seroprevalence and circulation at the time of delivery SARS-CoV-2 seroprevalence among parturient women in Philadelphia The "scar" of a 459 pandemic: Cumulative incidence of COVID-19 during the first trimester of pregnancy Seroprevalence analysis of SARS-CoV-2 in pregnant women along the first pandemic outbreak and 463 perinatal outcome CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort American journal of 469 obstetrics and gynecology. 2020. 470 35. Ministry of Health GoK. 2013 KENYA HOUSEHOLD HEALTH EXPENDITURE AND 471 UTILISATION SURVEY Seroprevalence of 473 SARS-CoV-2-specific antibodies in Sydney, Australia following the first epidemic wave A 477 systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, 478 and association with severity Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated 481 epidemic SARS-CoV-2-483 specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls Surveillance of endemic 486 human coronaviruses (HCoV-NL63, OC43 and 229E) associated with childhood pneumonia in Kilifi Improving 489 SARS-CoV-2 cumulative incidence estimation through mixture modelling of antibody levels